Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M, Croyle JA, Noorzad Z, Calagua C, MacDonald TY, Axcrona U, Bogaard M, Axcrona K, Scherr DS, Sanda MG, Johannessen B, Chinnaiyan AM, Elemento O, Skotheim RI, Rubin MA, Barbieri CE et al. (2022) Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci JCI Insight, 7 (4) DOI 10.1172/jci.insight.155309, PubMed 35050902 Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D et al. (2022) Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway J Transl Med, 20 (1), 225 DOI 10.1186/s12967-022-03432-5, PubMed 35568909 Skotheim RI, Axcrona U, Axcrona K (2022) Re: Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer Eur Urol, 81 (4), 431 DOI 10.1016/j.eururo.2021.12.031, PubMed 35031159 More publications